# Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2

> **NCT03220399** · PHASE1 · WITHDRAWN · sponsor: **NVP Healthcare**

## Conditions studied

- Healthy

## Interventions

- **DRUG:** NVP-1603-1 (P)
- **DRUG:** NVP-1603-2 (T)
- **DRUG:** NVP-1603-1 and NVP-1603-2 (P+T)

## Key facts

- **NCT ID:** NCT03220399
- **Lead sponsor:** NVP Healthcare
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-12-01
- **Primary completion:** 2020-03-28
- **Final completion:** 2020-07-31
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Decided to stop drug development
- **Last updated:** 2019-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03220399

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03220399, "Pharmacokinetic Interaction and Safety/Tolerability Between NVP-1603-1 and NVP-1603-2". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03220399. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*